Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) has received an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports.

Fintel reports that on February 28, 2025, William Blair initiated coverage of Terns Pharmaceuticals (NasdaqGS:TERN) with a ...

Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertiseFOSTER CITY, Calif., Feb. 20, ...

Equities researchers at William Blair started coverage on shares of Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) in a research note issued to investors on Friday, Marketbeat reports. The firm ...

Seasoned public company CFO with 25 years of leadership experience in biotechFOSTER CITY, Calif., Feb. 24, 2025 (GLOBE ...

In a report released today, Silvan Tuerkcan from JMP Securities maintained a Buy rating on Terns Pharmaceuticals (TERN – Research Report), with ...

The Company granted Mr. Gengos a new hire option to purchase 750,000 shares of Terns common stock. The option has a 10-year term and an exercise price per share equal to $3.73, which was the closing ...

Terns Pharmaceuticals, Inc., a biopharmaceutical company focused on developing small-molecule therapies for serious diseases, announced the appointment of Andrew Gengos as its new chief financial ...

FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage ...

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity.